Spreadsheet: 42c5b178-f852-4f70-b14d-6e0be706d8a8
Sheet: Mapping of HCDs

2014-15 tariff - mapping of the high cost drugs to their respective BNF categories.
 | Key:
 | Added/Altered in 2014-15
 | BNF category followed by a ">" symbol means that only that drug or drug sub category is listed
Drug by category | Drug (categorised by BNF where appropriate)
Cytokine Modulators | 1.5.3 >Drugs affecting the immune response>Cytokine Modulators^
 | 10.1.3 >Cytokine Modulators^
 | (includes Apremilast, [NAME], Teduglutide, [NAME] and Vercirnon)
Vasodilator antihypertensive drugs/Pulmanory Arterial Hypertension | 2.5.1 >Ambrisentan
 | 2.5.1 >Bosentan
 | 2.5.1 >Iloprost
 | 2.5.1 >Sildenafil * *([NAME] excluded only when used for Pulmanory Arterial Hypertension)
 | 2.8.1 >Epoprostenol
 | 7.4.5 >Tadalafil * *(Tadalafil excluded only when used for Pulmanory Arterial Hypertension)
 | (includes Macitentan, Nitric Oxide, Riociguat, Selexipag and [NAME] sodium)
Fibrinolytic drugs | 2.10.2 >Alteplase** **(Alteplase is dealt with as an adjustment under PbR)
Blood-related products | 2.11 >Blood-related products
Allergen Immunotherapy | 3.4.2 >Omalizumab
 | (includes Mepolizumab and Reslizumab)
Allergic Emergencies | 3.4.3 >Angioedema
 | (includes Ecallantide)
[NAME] surfactants | 3.5.2 >Beractant
 | 3.5.2 >Poractant alpha
Mucolytics | 3.7 >Dornase alfa
 | 3.7 >Ivacaftor
 | 3.7 >Mannitol (when delivered via nebulisation/inhalation)
Pulmonary Fibrosis | 3.11 >Pirfenidone
Hypnotics and anxiolytics | 4.1.1 >Sodium oxybate
Non-opioid analgesics | 4.7.1 >Ziconotide
Neurodegenerative Conditions | 4.9.1 >Co-careldopa internal tube intestinal gel*** ***(Only when used as intestinal gel with internal tube)
 | 4.9.3 >Tafamidis
Torsion Dystonias and other involuntary movements | 4.9.3 >Riluzole
 | 4.9.3 >torsion dystonias and other involuntary movements
Antibacterial Drugs | 5.1.2.3 >Aztreonam Lysine****
 | 5.1.4 >Tobramycin****
 | 5.1.7 >Colistimethate sodium****
 | [NAME]***
 | ****(when delivered via nebulisation/inhalation)
 | (includes Amikacin liposomal)
Antifungals | 5.2.1 >Triazole antifungals >Posaconazole
 | 5.2.1 >Triazole antifungals >Voriconazole
 | 5.2.3 >Polyene antifungals >Amphotericin >lipid formulations
 | 5.2.4 >Echinocandin antifungals >Anidulafungin
 | 5.2.4 >Echinocandin antifungals >Caspofungin
 | 5.2.4 >Echinocandin antifungals >Micafungin
 | (includes Isavuconazole)
AIDS/HIV antiretrovirals | 5.3.1
 | (includes Cobicistat, Dolutegravir, Elvitegravir, [NAME], Elvucitabine and Vicriviroc)
Cytomegalovirus infection | 5.3.2.2 >Cytomegalovirus infection
Viral Hepatitis (B&C) & Respiratory Syncytial Virus | 5.3.3
 | 5.3.5
 | 8.2.4 >Interferon alfa
 | (includes Alisporivir, Asunaprevir with [NAME], [NAME], [NAME], Nitazoxanide, Simeprevir, [NAME], [NAME] with [NAME] and Taribavirin)
Growth Hormone & Growth Hormone Receptor Antagonist | 6.5.2 >Tolvaptan
 | 6.5.1 >Anterior pituitary hormones>growth hormone receptor antagonist
 | 6.5.1 >Anterior pituitary hormones>growth hormone
 | 6.7.4 >Mecasermin
 | (includes Octreolin, Tesamorelin and Lixivaptan)
Drugs affecting bone metabolism | 6.6.1 >Teriparatide
 | 6.6.1 >Parathyroid hormone
Immunomodulating drugs | 8.1 >Dexrazoxane
 | 8.1.3 >Cladribine^
 | 8.2.4 >Interferon alfa>[NAME]
 | 8.2.4 >Interferon beta
 | 8.2.4 >Aldesleukin
 | 8.2.4 >Glatirimer
 | 8.2.4 >Lenalidomide^
 | 8.2.4 >Natalizumb
 | 8.2.4 >Thalidomide^
 | 8.2.4 >Fingolimod
 | (includes Dimethyl fumarate, Laquinimod, Nintedanib, Peginterferon Beta-1a, [NAME], Rilonacept^ and Teriflunomide)
Myelodysplastic Syndrome | 8.1.3 >Azacitidine^
 | 8.1.3 >Decitabine^
 | Rigosertib^ (no BNF category available)
Antineoplastic drugs | 8.1.5 >Bevacizumab^
 | 8.1.5 >Bortezomib^
 | 8.1.5 >Cetuximab^
Protein kinase inhibitors | 8.1.5 >Protein kinase inhibitors^
 | (includes Fostamatinib disodium^, Masitinib^ and Pacritinib^)
Corticosteroids and other immunosuppressants | 8.2.2 >Basiliximab
 | [NAME] (no BNF category available)
Drugs affecting the Immune response | 8.2.3 >Belatacept
 | 8.2.3 >Alemtuzumab^
 | 9.1.7 >Plerixafor
 | 10.1.3 >Belimumab
 | 13.5.3 >Efalizumab
 | 13.5.3 >Ustekinumab
 | (includes [NAME])
[NAME] | 8.3.4.3
 | (includes Fibroblast growth factor 1 gene therapy)
Paroxysmal nocturnal haemoglobinuria | 9.1.3 >Eculizumab
Platelet Disorder Drugs | 9.1.4 >Eltrombopag
 | 9.1.4 >Romiplostim
 | (includes [NAME])
Drugs used in hypoplastic, haemolytic, and renal anaemias | 8.2.2 >Antilymphocyte globulin
 | 9.1.3 >[NAME]
 | 9.1.3 >Iron Overload (For chronic iron overload)
Drugs used in Metabolic disorders | 8.2.4 >Canakinumab
 | 9.4.1 >Sapropterin
 | 9.8.1 >Carnitine deficiency
 | 9.8.1 >[NAME]'s disease
 | 9.8.1 >Gaucher's disease
 | 9.8.1 >Mucopolysaccharidosis
 | 9.8.1 >Nephropathic cystinosis
 | 9.8.1 >Pompe Disease
 | 9.8.1 >Tyrosinaemia type I
 | 9.8.1 >Urea cycle disorders
 | 9.8.1 >Homocystinuria
 | 9.8.1 >Other metabolic disorders
 | (includes [NAME], [NAME] bitartrate, [NAME], [NAME], Human Arginate,Sebelipase alfa and Taliglucerase alfa)
Drugs used in Neutropenia | 9.1.6^
 | (includes Lipegfilgrastim^)
Parenteral Nutrition | 9.3 >Parenteral Nutrition (after 14 days or when the patient is receiving parenteral nutrition prior to admission)
Gout and cytotoxic-induced hyperuricaemia | 10.1.4 >Hyperuricaemia associated with cytotoxic drugs
 | Pegloticase (no BNF category available)
[NAME] | 10.2.1 >Amifampridine phosphate
 | 10.2.1 >Fampridine
 | (includes [NAME]*)
Enzymes | 10.3.1 >Collagenase (only when used in outpatients)
[NAME] | 11.4.1 >Dexamethasone intravitreal implant
 | Fluocinolone acetonide (only when used as an intravitreal implant) (no BNF category available)
Retinal disorders/intraocular lens replacement surgery | 11.8.2 >Ocriplasmin
 | (includes Ketorolac with Phenylephrine)
Subfoveal choroidal neovascularisation | 11.8.2 >Aflibercept
 | 11.8.2 >Pegaptanib
 | 11.8.2 >Ranibizumab
 | 11.8.2 >Verteporfin
Skin Conditions | 13.5.1 >Alitretinoin
 | Afamelanotide (no BNF category available)
Intravenous/subcutaneous human normal immunoglobulins | 14.5.1 >Normal immunoglobulin>for intravenous use
 | 14.5.1 >Normal immunoglobulin>for subcutaneous use
Bone morphogenetic protein | No BNF Category available
 | (includes [NAME] and Eptotermin alpha)
Poisoning | Emergency treatment of poisoning >Other poisons >Ethylene glycol and methanol >Fomepizole
 | (includes Digoxin immune fab)
Hypertension and heart failure | Serelaxin (no BNF category available)
Lipid-regulating drugs | Lomitapide (no BNF category available)
Drug (by category) | Drug (categorised by BNF where appropriate)
Hormone antagonists | 8.3.4 >Abiraterone
 | 8.3.4.2 >Enzalutamide
^(For non-chemotherapy indications - chemotherapy is dealt with separately)
*(For non-cystic fibrosis indications)